Pressmeddelande —
SHIFT trial presents positive results
Positive results from the SHIFT trial were published in the Lancet online, August 29, 2010. With more than 6500 patients in 37 countries it is the largest heart failure trial published to date. Contract research Organization A+ Science managed the coordination of sites from start up to close-out in 6 European countries.
The SHIFT trial evaluated Ivabradine, an If inhibitor already indicated for the treatment of coronary artery disease. The results showed a significantly reduced risk of cardiovascular death and hospital admissions when added to standard treatments in patients with chronic heart failure and elevated heart rates.
Ämnen
- Hälsa, sjukvård, läkemedel
Kategorier
- contract research organisation
- cro
Contract Research Organization A+ Science provides clinical services throughout the life cycle of pharmaceuticals and medical devices. We create customer value through predictability and speed, an approach partly reinforced with what we like to call controlled patient recruitment.
Being part of a strategic CRO partnership, represented in 17 university cities in the Nordic countries and the Baltic States further enhances our offer, creating unmatched access to clinical trial resources in Northern Europe. In addition our Site Management Services provide resources to investigators, making clinical trials even more customizable.
